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Proteinase 3 gene polymorphisms and Wegener’s granuloma- Wegener’s granulomatosis (WG) is a rare primary sys-
tosis. temic vasculitis characterized by granulomatous lesions
Background. Wegener’s granulomatosis (WG) is a rare sys- of small vessels and the presence of cytoplasmic antineu-temic autoimmune disease characterized by small-vessel vascu-
trophil cytoplasmic autoantibodies (c-ANCAs) in seralitis leading to organ damage and the presence of antineutrophil
of the patients [1]. ANCAs have been shown to activatecytoplasmic autoantibodies (ANCAs). ANCAs were shown to
be involved in the pathogenesis of the disease by increasing primed polymorphonuclear cells (PMNs) and endothe-
adhesion of polymorphonuclear cells (PMNs) to endothelial lial cells, increasing adhesion and subsequent release of
cells and through activation of primed PMN. The main autoan- enzymes, lipid metabolites, and toxic oxygen radicalstigen of ANCA in WG is proteinase 3 (PR3), a neutrophil-
from PMNs [2]. The main autoantigen of c-ANCA isand monocyte-derived neutral serine protease. The association
proteinase 3 (PR3), which is localized in the azurophilicof WG with individuals continuously expressing a high level
of PR3 on the surface of PMNs suggests that PR3 variants or granules as well as in a readily plasma membrane-mobi-
altered regulation of PR3 expression might be directly involved lizable pool of secretory vesicles [3] of PMNs and translo-
in the pathogenesis of the disease.
cates to the cell surface after activation of PMNs. PR3Methods. We screened the entire coding and promoter se-
is involved in the destruction of phagocytosed microor-quences of the PR3 gene for polymorphisms by means of polymer-
ase chain reaction single-strand conformation polymorphism ganisms. It cleaves the connective tissue protein elastin,
(PCR-SSCP). Allelic, genotypic, and haplotype frequencies were exhibits chemotactic properties, and regulates the prolif-
compared between 79 WG patients and a cohort of 129 healthy eration of granulopoietic progenitor cells [4]. The “defec-controls.
tive” PiZ-allele of the PR3 inhibitor a1-antitrypsin isResults. Seven single-nucleotide polymorphisms (SNPs), one
associated with WG, another hint for a pathogenic roleamino acid change (Val119Ile), one 84 bp insertion/deletion,
and a microsatellite were identified. An association with WG of PR3 in the development of WG [5–7]. Together with
could be demonstrated for the A-564G polymorphism in the two other neutral proteases, the leukocyte elastase
PR3 promoter affecting a putative transcription factor-binding
(ELA2) and azurozidin (AZU), the PR3 gene is localizedsite.
within a 50 kb region on chromosome 19p13.3. Recently,Conclusions. This study excludes certain PR3 epitope vari-
ants as autoantigenic stimuli in WG, since the Val119Ile poly- two other serine proteases were identified in near prox-
morphism showed no differences between patients and con- imity to the AZU-PR3-ELA2 cluster [8]. All five genes
trols. Overexpression of PR3, however, might predispose the code for a family of neutral serine proteases. They are
patient to the development of autoimmune ANCA-associated
transcribed in the same orientation; they have the samevasculitis.
principal structure consisting of five exons and similar
exon/intron boundaries.
The aim of our study was to investigate whether ge-
netic variants of the PR3 gene are associated with the
development of PR3-ANCA1 systemic vasculitis.1 Present address: SmithKline Beecham Pharmaceuticals, Harlow, Es-
sex, CM19 5AW England, United Kingdom.
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Table 1. Oligonucleotides used for PCR-SSCP and microsatellite analysis
PR3-region Name Primer sequence
Promotor Ia 34U 59-CTG CAG GGT GCT AGG CAT CA-39
148L 59-CAG GAT TCT CAA TCA AGG GGT G-39
Promotor Ib 108U 59-GTG TCC TCA GAC CTC ACC CAG GG-39
230L 59-GCC CTC AGT GCC TCA CCT G-39
Promotor II 195U 59-AGA CAA AAC TGG CAG GAG GA-39
421L 59-CAC AGC CCT CAG AGC AAC AC-39
Promotor III 391U 59-GGC GTC TCC TTG TGG GTG GC-39
573L 59-CCA CTT CCT CCT TTT GCC TTG GG-39
Promotor IV 527U 59-CCA AAG CCC CCA CCT CCT-39
731R 59-ACT CAC CGC TCA GCA GCA AG-39
Exon 1 347F 59-AAG AGG AGC TTG ACC GTG GG-39
511R 59-TAT TTC CCC ACA ATC CAC CG-39
Intron 1 84 bp ins/del 579F 59-ACC CAG CCT TCA GCA AAT G-39
1075R 59-TGC TCT CTT CTT CCC CTG ATT-39
Exon 2 2810F 59-CGC CTG GAC TCC CCC CCT GC-39
3008R 59-CGG GCG GAC AGG GGT GTG GA-39
Exon 3 3220F 59-CCA GGG CGC CGA GGA GTG AC-39
3418R 59-CTC TGC CGT GCC CCT CCG AG-39
Exon 4 5190F 59-CCT GGA AGC AGT GCT CAC CG-39
5518R 59-AGA GGT GGC GTG GAA CCC TC-39
Intron 4 microsatellite 6148F 59-CAG AGC GAG ACT CTG TCG CA-39
6433R 59-CTG TTT CAG AAT AAA AAT GCT TCC-39
Exon 5 6501F 59-TGA CTG GCT GTC CCC ATC TC-39
6839R 59-TCT GTC CAA CGC TCC GCC TC-39
Abbreviations are: PCR-SSCP, polymerase chain reaction single strand conformation polymorphism; ins/del, insertion/deletion.
diagnosis of WG was determined in accordance with the urea. The gels were run at 48C at 55 W. The V119I
polymorphism was retyped by demonstrating an addi-definitions for systemic vasculitides by the Chapel Hill
consensus conference (CHC) [9] and the criteria defined tional TaiI restriction site in exon 3. For DNA sequenc-
ing, PCR products were gel purified by means of a gelby the American College of Rheumatology (ACR) [10].
All patients originated from Bavaria, gave informed con- extraction kit (Quiaquick; Quiagen, Chatsworth, CA,
USA) and were sequenced with the dye terminator cyclesent, and were diagnosed and treated in the departments
of medicine of the following hospitals: Medizinische Klinik sequencing on an ABI377 automatic sequencer.
und Poliklinik, Klinikum Innenstadt, Medizinische Klinik I,
StatisticsKlinikum Großhadern, Ludwig-Maximilians-University,
Mu¨nchen; Department of Medicine, Klinikum Hohe Allele and genotype frequencies were compared be-
tween the groups with the x2 or Fisher’s exact test. Hap-Warte, Bayreuth; and Department of Nephrology, St.
Joseph Hospital, Regensburg, Germany. lotype frequencies were estimated using the software
ARLEQUIN using the maximum likelihood methodSerum PR3-ANCAs were demonstrated by indirect
immunofluorescence using ethanol-fixed neutrophils, [13]. Prediction of transcription factor (TF) binding sites
was performed using the program Transcription Elementand their reactivity with PR3 was confirmed in enzyme-
linked immunosorbent assays (ELISA) specific for PR3 Search (TES) [14].
(Elias, Freiburg, Germany). The clinical parameters of
our cohort have been described previously [11].
RESULTS
A matched group of 129 healthy southern German
Polymorphisms in the PR3 genedonors were used as controls.
Using SSCP analyses, altogether eight single-nucleo-
DNA analyses tide polymorphisms (SNPs) were detected in the pro-
moter and in the exonic sequences of the PR3 gene (Fig. 1).DNA was extracted according to the protocol by
Miller, Dykes, and Poleski [12]. For the promoter se- In the coding sequence, one SNP was found, changing
the first base of the codon 119 from A to G leading toquence analyses, primers were designed in order to am-
plify five overlapping PCR fragments. Each of the five an amino acid change from Valin to Isoleucin. Another
polymorphism (C503T) was detected in intron 1, 31 bpexons were amplified, including the relevant splice sites.
The primers used in the study are listed in Table 1. from the 39 end of the first exon. By comparison of
sequences from public databases, an 84 bp deletion/inser-Analyses of single-strand conformation polymorphism
(SSCP) were performed on 6% polyacrylamide (PAA) tion polymorphism was found in intron 1. The sequences
of both alleles are shown in Figure 2. In intron 4, agels with either 10% glycerol or 5% glycerol and 1 mol/L
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Fig. 1. Schematic overview of the proteinase 3 (PR3) gene with the corresponding polymorphisms (top) and transcription factor (TF) binding
site changes (bottom) as estimated by the program, Transcription Element Search (TES).
Fig. 2. Insertion/deletion polymorphism in intron 1 of the PR3 gene.
Table 2. Diallelic polymorphisms in the PR3 gene as well as allele
frequencies in patients with WG and the control groups, including
the corresponding P and OR values
Polymorphism WG N Controls N P OR
119Val/Ile 64.7%/35.3% 75 59.4%/40.6% 117
Intron 1 ins/del 67.6%/32.4% 51 56.9%/43.1% 116 .0.05 1.6
503C/T 60.8%/39.2% 74 69.0%/31.0% 79 .0.05 1.4
228C/T 84.6%/15.4% 68 77.5%/22.5% 129 .0.05 1.6
2172C/T 78.2%/21.8% 62 78.7%/21.3% 101
2236C/T 84.9%/15.1% 63 78.9%/21.1% 102 .0.05 1.5
2413G/C 60.2%/39.8% 65 52.0%/48.0% 99 .0.05 1.4
2536C/T 77.3%/22.7% 75 76.2%/23.8% 107
2564A/G 50.8%/49.2% 66 65.6%/34.4% 106 ,0.01 0.5
Abbreviations are: WG, Wegener’s granulomatosis; N, number; OR, odds ratio.
Table 3. Allelic frequencies of the intron 4 microsatellite in patients
with Wegener’s granulomatosis (WG) and controls Fig. 3. PR3 haplotype frequencies [A-564G; C503T] in controls and
patients with Wegener’s granulomatosis as estimated by the programMicrosatellite allele
Arlequin. Symbols are: (j) Wegener’s granulomatosis; ( ) controls.
1 2 3 4 5 6 71819 N
WG 3.2% 2.5% 37.3% 32.3% 20.3% 4.4% 0% 79
Controls 6.5% 0% 45.2% 25.7% 20.0% 1.3% 1.2% 115
Haplotype frequency estimation with the software Ar-
lequin revealed a strong preponderance of the halpotype
[2564G; 503C] in patients with WG (39.4%, SD 5 4.3)
when compared with the control group (13.4%, SD 5highly polymorphic (ga) microsatellite was identified. Six
additional polymorphisms were detected in the promoter 4.7, P , 0.00001, OR 5 4.2; Fig. 3).
region of the PR3 gene: C-28T, C-172T, C-236T, G-413C,
Promoter polymorphisms change potential TFC-536T, and A-564G.
binding sites
Allele and haplotype frequencies Analysis of the polymorphisms in the promoter region
of the PR3 gene revealed several changes in sequencesAllele frequencies of diallelic polymorphisms in pa-
tients with WG and in healthy controls are shown in for TF binding sites by means of TES. The A allele of
the A-564G polymorphism is a CACCC-TF recognitionTable 2. The allele frequency distribution of the (ga)
microsatellite in intron 4 is shown in Table 3. No simple sequence, whereas the G allele represents a GC-box
element, which is the Sp1-TF binding site. Furthermore,association of a certain allele could be demonstrated.
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the T allele of the C-536T does not bind the CAC-TF. allele of the intronic polymorphism. The functional sig-
Similarly, the T allele of the C-236T polymorphism adds nificance of this latter polymorphism is not obvious. The
a T-cell transcription factor E box (TFEB) recognition vicinity to exon/intron boundaries on both sides might
site (Fig. 1). influence splicing efficacy. On the other hand, a putative
enhancer/repressor element might be influenced as well.
Increased expression of PR3 may be due to an interac-DISCUSSION
tion of SP1 with a protein that selectively recognizes
The development of autoimmune phenomena such as the C allele of the C503T polymorphism. However, the
autoantibodies is still not clearly understood, although relevance of the [2564G; 503C] haplotype for the expres-
genetic factors are known to play a role in many of sion of PR3 can be evaluated only in functional experi-
these processes. In WG and other antibody-associated ments. Such expression studies are currently underway
systemic vasculitis, genetic factors involved in the patho- in our laboratory. Furthermore, there are additional
genesis of the diseases have been described recently hints in our patient group for the existence of an ex-
[11, 15]. However, the contribution of genetic variants tended haplotype spanning over the entire PR3 locus.
of PR3, which is the autoantigen in WG, is entirely un- The [2564G; 503C] haplotype appears to be the statisti-
known. Several studies described epitopes on PR3, which cally demonstrable core part of it.
are recognized by autoantibodies from sera of patients From the results of our experiments, we conclude that
with WG [16, 17]. In order to identify genetic factors that the PR3 locus is involved in the pathogenesis of WG.
might predispose to the development of PR3-ANCA, we The association of the disease with the [2564G; 503C]
have screened the entire coding sequence of PR3 in a haplotype in the PR3 gene represents further evidence
cohort of 79 patients. The Val119Ile previously described for the etiologic role of common polymorphisms in the
[18] is located in a relevant surface region of PR3 [17];
development of autoimmune vasculitides such as WG.
however, no statistically significant over-representation
was obvious for this antigenic variant in our panel of
ACKNOWLEDGMENTSWG patients. However, beside the 119Val, there are at
This work was supported by a FoRUM grant (F 179/99). The authorsleast seven additional major immunodominant amino
thank Professors E. Held, D. Schlo¨ndorff, D. Seybold, F.E. Scherber-acid residues on the surface of PR3 [17]. Although our ich, and W. Samtleben for enabling us to study patients treated in their
data exclude a major contribution of the Val119Ile poly- departments of medicine.
morphism in the etiology of WG, it still may be involved
Reprint requests to Dr. Martin Gencik, Molekulare Humangenetik,in the pathogenesis of a subgroup of patients.
Ruhr-Universita¨t Bochum, D-44780 Bochum, Germany.
A second possibility for increased autoantigenicity of E-mail: martin.gencik@ruhr-uni-bochum.de
PR3 might be an altered expression on the cell surface.
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